WO1998008847A1 - Derives 6,5-hetero-bicycliques substitues - Google Patents

Derives 6,5-hetero-bicycliques substitues Download PDF

Info

Publication number
WO1998008847A1
WO1998008847A1 PCT/IB1997/000922 IB9700922W WO9808847A1 WO 1998008847 A1 WO1998008847 A1 WO 1998008847A1 IB 9700922 W IB9700922 W IB 9700922W WO 9808847 A1 WO9808847 A1 WO 9808847A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
trimethyl
ethyl
methyl
Prior art date
Application number
PCT/IB1997/000922
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21823717&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998008847(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EA199900165A priority Critical patent/EA002769B1/ru
Priority to CA002263566A priority patent/CA2263566C/fr
Priority to EP97930697A priority patent/EP0923582B1/fr
Priority to HU9903965A priority patent/HUP9903965A3/hu
Priority to BR9711970A priority patent/BR9711970A/pt
Priority to IL12756697A priority patent/IL127566A0/xx
Priority to AU34561/97A priority patent/AU735401B2/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to JP51142998A priority patent/JP3621706B2/ja
Priority to PL97332040A priority patent/PL332040A1/xx
Priority to DE69736711T priority patent/DE69736711T2/de
Priority to NZ333302A priority patent/NZ333302A/xx
Priority to SK233-99A priority patent/SK23399A3/sk
Publication of WO1998008847A1 publication Critical patent/WO1998008847A1/fr
Priority to IS4963A priority patent/IS4963A/is
Priority to BG103189A priority patent/BG103189A/xx
Priority to NO19990927A priority patent/NO313636B1/no
Priority to US10/160,206 priority patent/US6900217B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention relates to certain pharmaceutically active substituted 6,5-hetero- bicyciic derivatives, pharmaceutical compositions containing them and methods of administering them to subjects in need of their corticotropin releasing factor antagonist activity.
  • the substituted heterocyclic derivatives claimed in this case exhibit activity as corticotropin releasing factor (hormone) CRF (CRH) antagonists.
  • CRF corticotropin releasing factor
  • CRF antagonists are mentioned in U.S. Patents 4,605,642 and 5,063,245 referring to peptides and pyrazolinones, respectively. They are also referred to in the following: PCT Patent Application PCT/IB95/00439, which designates the United States and was filed on June 6, 1995 and published on December 14, 1995; PCT Patent Application PCT/IB95/00373, which designates the United States and was filed on May 18, 1995 and published on December 21 , 1995; U.S. Patent Application 08/448,539, which was filed in the PCT on Nov. 12, 1993 and entered the U.S. national phase on June 14, 1995; PCT Patent Application WO 95/10506, which was filed on October 12, 1993 and published on April 20, 1995, and U.S.
  • CRF antagonists The importance of CRF antagonists is set out in the literature, e& , P. Black, Scientific American SCIENCE & MEDICINE.1995. p. 16-25; T. Lovenberg et al.. Current Pharmaceutical Design. 1995, 1, 305-316; and United States Patent 5,063,245, which is referred to above. A recent outline of the different activities possessed by CRF antagonists is found in M. J. Owens et al., Pharm. Rev.. Vol. 43, pages 425 to 473 (1991 ), also incorporated herein by reference.
  • CRF antagonists are effective in the treatment of a wide range of stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression, recurrent depression, child abuse induced depression, postpartum depression, dysthemia, bipolar disorders and cyclothymia; chronic fatigue syndrome; eating disorders such as anorexia and bulimia nervosa; generalized anxiety disorder; panic disorder; phobias; obsessive-compulsive disorder, post-traumatic stress disorder, pain perception such as fibromyalgia; headache; gastrointestinal diseases; hemorrhagic stress; ulcers; stress-induced psychotic episodes; fever; diarrhea; post-operative ileus, colonic hypersensitivity; irritable bowel syndrome; Crohn's disease; spastic colon; inflammatory disorders such as rheumatoid arthritis and osteoarthritis; pain; asthma; psoriasis; allergies; osteoporosis; premature birth; hypertension, congestive heart failure;
  • the compounds of this invention are also believed to be inhibitors of CRH binding protein and therefore useful in the treatment of disorders the treatment of which can be effected or facilitated by inhibiting such protein. Examples of such disorders are Alzheimer's disease and obesity.
  • A is nitrogen or CR 7 ;
  • J and K are each independently nitrogen or carbon and both J and K are not nitrogens ;
  • G is nitrogen or carbon;
  • -NR'R 2 or -CR 1 R 2 R 10 may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ 3 wherein Z 3 is hydrogen, C,-C 4 alkyl, benzyl or C,-C 4 alkanoyt;
  • R 3 is hydrogen, C,-C 4 alkyl, -0(C 1 -C 4 alkyl), chloro, fluoro, bromo, iodo, (C,-C 2 alkylene)-0-(C,-C 2 alkyl), (C r C 2 alkylene)-OH, or -S(C,-C alkyl); each R 4 is, independently, hydrogen, (C,-C ⁇ alkyl),.
  • R 8 is hydrogen or C,-C 4 alkyl
  • R 5 is phenyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl and wherein each of the foregoing R 5 groups is substituted with from one to four substituents R 13 wherein one to three of said substituents may be selected, independently, from fluoro, chloro, C,-C ⁇ alkyl and -0(0, -C ⁇ alkyl) and one of said substituents may be selected from bromo, iodo, formyl, OH, (C,-C 4 alkylene)-OH, (C 1 -C 4 alkylene)-0-(C C 2 alkyl), -ON, -CF 3 , -N0 2 , -NH 2 , -NH(C,-C 4 alkyl), -N(C,-C 2 alkyl)(C,-C ⁇ alkyl), -OCO(C,-C 4 alkyl), (C C 4 alkylene
  • halo e.g., chloro, fluoro, iodo or bromo
  • R 0 is hydrogen, hydroxy, methoxy or fluoro
  • R 1 1 is hydrogen or C,-C 4 alkyl
  • R 0 is hydrogen, hydroxy, methoxy or fluoro
  • R 1 1 is hydrogen or C,-C 4 alkyl
  • the ring containing D, E, G, K and J is a 5-membered heteroaromatic ring, it may be, e ⁇ g., pyrazolo, imidazolo, thieno, furano, thiazolo, oxazolo, triazolo or thiadiazolo.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight branched or cyclic moieties or combinations thereof.
  • alkoxy as used herein, unless otherwise indicated, means -0-alkyl, where “alkyl” is defined as above.
  • More specific embodiments of this invention include compounds of the above formula I wherein B is -CHR'R 2 , -NR'R 2 , -NHCHR'R 2 , -OCHR'R 2 or -SCHR'R 2 , and R 1 is C,-C 6 alkyl, which may optionally be substituted with one hydroxy, fluoro, CF 3 or C,-C 4 alkoxy group and which may optionally contain one double or triple bond; and R 2 is benzyl or C,-C ⁇ alkyl, which may optionally contain one double or triple bond, wherein said C,-C ⁇ alkyl and the phenyl moiety of said benzyl may optionally be substituted with one fluoro, CF 3 , C,-C 2 alkyl, C,-C 2 alkoxy or chloro group.
  • R 3 is methyl, ethyl, chloro or methoxy
  • R 4 and R ⁇ are selected from hydrogen, methyl and ethyl
  • R 5 is di- or tri-substituted phenyl, pyridyl, or pyrimidyl, in which the two or three substitutents on said phenyl, pyridyl or pyrimidyl are selected, independently, from C,-C 4 alkyl, -0-(C,-C 4 alkyl), (C,-C 2 alkyl)-0-(C,-C 4 alkyl), -CF 3 , -OCF 3 , -CHO, -(C,-C 4 alkyl)-OH, cyano, chloro, fluoro, bromo and iodo, wherein each of the forgoing C,-C 4 alkyl groups may optionally contain one double or triple bond;
  • Other more specific embodiments of this invention include
  • This invention also relates to a pharmaceutical composition for the treatment, prevention or inhibition of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as f ⁇ bromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever
  • porcine stress syndrome bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfract dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; and hypoglycemia in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in the treatment of such disorder, and a pharmaceutically acceptable carrier.
  • the invention also relates to a method for the treatment, prevention or inhibition of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitator by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome; Crohn's disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-inducedfever; human immuno
  • This invention also relates to a method of treating or preventing a disorder or condition, the treatment or prevention of which can be effected or facilitated by inhibiting CRH binding protein, in a mammal, including a human, comprising administering to said mammal a CRH binding protein inhibiting amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a pharmaceutical composition for treating or preventing a disorder or conditon, the treatment or prevention of which can be effected or facilitated by inhibiting CRH binding protein in a mammal, including a human, comprising a CRH binding protein inhibiting amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • This invention includes all optical isomers and other stereoisomers of compounds of the formula I. When such compounds contain one or more chiral centers, it is understood that the invention includes the racemic mixtures as well as all individual enantiomers and diastereomers of such compounds, and mixtures thereof.
  • T is chloro, bromo, iodo or -OS0 2 CF 3 ;
  • W is cyano, formyl, or -COO(C 0 -C 4 alkyl) and A, J, K, D, E, G, R 3 , and R 5 are as defined above with reference to formula I.
  • V-a N-a, T Cl , Br, 1
  • ⁇ W CN , • C00(C 1 -C 4 alkyl)
  • Suitable solvents for this reaction include DMSO, NMP, dimethylacetamide and THF.
  • BH may be used as both the reagent and the base.
  • Other bases such as potassium or sodium carbonate, a trialkylamine, a potassium or sodium (C,-C 4 alkoxide) and sodium hydride may also be used.
  • R 7 is an electron withdrawing group such as -COO(C r C 4 alkyl) or CN
  • the reaction generally is carried out at a temperature between about room temperature and about 100°C.
  • R 7 is a non-electron withdrawing group
  • the reaction temperature can generally range from about 50°C to about 270°C and the pressure can generally range from about 4 psi to about 300 psi.
  • a pressure reactor may be used.
  • the compounds of formula I may be prepared by reacting a compound of the formula II wherein T is bromo or iodo with 1 equivalent or an excess of BH and a base such as sodium or potassium carbonate or a sodium or potassium (C,-C 4 alkoxide), in the presence of a palladium (II) or a palladium (0) catalyst such as Pd(OAc) 2 or Pd(PPh 3 ) 4 , together with a racemic or chiral phosphino agent such as 2,2-bis(diphenylphosphino)-1 ,1 -binaphthyl (BINAP).
  • a base such as sodium or potassium carbonate or a sodium or potassium (C,-C 4 alkoxide
  • a palladium (II) or a palladium (0) catalyst such as Pd(OAc) 2 or Pd(PPh 3 ) 4
  • a racemic or chiral phosphino agent such as 2,2-bis(diphenylpho
  • premade Pd(ll)(BINAP) may be used in an appropriate inert (Le., inert with respect to the reaction at hand) solvent such as toluene, xylene, dioxane or sulfolane, at a temperature from about room temperature to about 180°C, preferably at about reflux temperature.
  • inert Le., inert with respect to the reaction at hand
  • solvent such as toluene, xylene, dioxane or sulfolane
  • -NHCR'R ⁇ 1 1 may be prepared by reacting compounds in the formula II wherein T is chloro, bromo or iodo with a compound of the formula BH in the presence of a base which is capable of deprotonation of BH (e.g., sodium or potassium hydride, or an organometallic base such as sodium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, a sodium C,-C 4 alkoxide or n-butyllithium), in an inert organic solvent such as tetrahydrofuran, acetonitrile, dimethylsulfoxide, acetone, a C 2 -C 5 alcohol, chloroform, benzene, xylene, toluene, N,N- dimethylformamide (DMF), methylene chloride, 1 -methyl-2-pyrrolidinone or a mixture of two or more of the above
  • reaction of a compound of the formula I wherein B is -CR' 'R 2 'OH, (wherein R r and R 2' are defined as R 1 and R 2 , respectively, except that R v may not be R 1 and R 2' may not be R 2 ), wfth an acid such as concentrated sulfuric acid in acetic acid, or a Burgess inner salt such as (carboxysulfamoyl)triethylammonium hydroxide methyl ester, will yield a compound of the formula I wherein B is -C( CR 2 R , 1 )R 1 .
  • an appropriate inert solvent such as a C,-C 4 alkanol or acetic acid.
  • Compounds in formula II may be prepared from compounds of the formula IV or V as described below.
  • Compounds of formula II wherein T is chloro, bromo or iodo can be prepared by reacting compounds of the formula IV with from one equivalent to an excess of P0T 3 (wherein T is chloro, bromo or iodo) in the presence or absence of a di(C,-C 4 alkyl)aniline, preferably diethylaniline, with or without a solvent (such as dichloroethane, DMF, dimethylsulfoxide (DMSO) or acetamide), at a temperature from about room temperature to about 180°C, preferably from about 100°C to about 150°C.
  • a solvent such as dichloroethane, DMF, dimethylsulfoxide (DMSO) or acetamide
  • compounds of formula II wherein T is chloro, bromo or iodo can be prepared by reacting the corresponding compounds of formula II wherein T is -0- S0 2 CF 3 with a sodium or potassium halide, in an appropriate inert solvent such as THF, sulfolane, DMSO, DMF or acetonitrile, at a temperature from about 60° C to about 180°C
  • Compounds of formula II wherein T is -OS0 2 CF 3 can be prepared by reacting compounds of formula IV with Tf 2 0 in the presence of a base such as triethylamine or pyridine, in an appropriate inert solvent such as THF, m ⁇ thylen ⁇ chloride, dioxane, ether or toluene, at an temperature from about 0°C to about 50°C, preferably from about 0°C to about room temperature.
  • compounds of formula II wherein T is chloro, bromo or iodo may be prepared by reacting compounds of formula V with a (0,-C j alkyl)-nltrite and Cu(l)T 2 (wherein T is chloro, bromo or iodo) in an appropriate inert solvent such as acetonitrile, acetone, methylene chloride, THF, dioxane, benzene, toluene, dichloroethane, DMF, DMSO or N-methylpyrrolidinone (NMP) at a temperature from about room temperature to about 150°C, preferably from about 40°C to about 100°C.
  • an appropriate inert solvent such as acetonitrile, acetone, methylene chloride, THF, dioxane, benzene, toluene, dichloroethane, DMF, DMSO or N-methylpyrrolidinone (NMP)
  • Compounds of the formula IV may be prepared by reacting the appropriate compounds of formula V with sodium nitrite (NaN0 2 ) in an aqueous acid such as sulfuric acid, acetic acid or phosporic acid, with or without an organic solvent, preferably in acetonitrite (CH 3 CN) or acetone.
  • sodium nitrite NaN0 2
  • an aqueous acid such as sulfuric acid, acetic acid or phosporic acid
  • organic solvent preferably in acetonitrite (CH 3 CN) or acetone.
  • Compounds of formula III wherein W is cyano can be prepared by reacting the corresponding compounds of formula II wherein T is chloro, bromo or iodo with potassium cyanide, copper cyanide, sodium cyanide or a di(C 1 -C 4 alkyl)aluminum cyanide in an appropriate inert solvent such as dimethylsulfoxide, DMF, toluene or xylene, at temperature from about room temperature to about 180°C, preferably from about 60°C to about 150°C, with or without Pd(ll)0Ac or Pd(0)(PPh 3 ) 4 .
  • an appropriate inert solvent such as dimethylsulfoxide, DMF, toluene or xylene
  • Compounds of formula III wherein W is -CHO or -COOH may be prepared by reacting compounds in formula II wherein T is bromo or iodo with an organoiithium reagent such as t-BuLJ, s-BuLi, or n-Bu ⁇ in an appropriate inert solvent such as THF, dioxane, ether, benzene or methylene chloride, at temperature from about -120°C to about room temperature, preferably from about -110°C to about -60°C, followed by quenching with an appropriate electrophile such as DMF or C0 2 (gas or dry ice), to give compounds of formula III wherein W is -CHO and -COOH, respectively.
  • organoiithium reagent such as t-BuLJ, s-BuLi, or n-Bu ⁇
  • an appropriate inert solvent such as THF, dioxane, ether, benzene or methylene chloride
  • a protecting group may be used at any stage of the various syntheses described above at which it is workable, or an ester group may be reduced to the corresponding C,-C 4 alkyl group at any convenient stage.
  • Compounds of formula I - XVIII, wherein R 3 is -0(C,-C 4 alkyl) or -S(C,-C 4 alkyl) can be prepared by reacting the corresponding compounds wherein R 3 is chloro, bromo or iodo, with a r ⁇ ,;ieophile such as a C,-C 4 alkanol or a C,-C 4 alkanethiol, in the presence of an organic or inorganic base.
  • Suitable bases for such a reaction include sodium and sodium hydride.
  • reaction conditions are: a) heating in polyphosphoric acid; b) heating in toluene, benzene or xylene in the presence of acid catalyst (such as p-TsOH, sulfuric acid or HCI(g)) using a Dean-Stark trap; or c) heating in an appropriate solvent such as dichloroethane, diphenylether (Ph 2 0) or Dowtherm A in the presence of a Lewis acid such as SnCI 4 , ZnCl j /HCI or AICI 3 .
  • acid catalyst such as p-TsOH, sulfuric acid or HCI(g)
  • Compounds of formula IV-c wherein A is N and G, J, and K are carbon may be prepared, as shown in Scheme 3, by reacting compounds of formula VI with (R 3 CO) 2 0, R 3 COOH or R 3 CO(OC,-C 2 alkyl) 3 , in acetic acid or an appropriate inert organic solvent such as toluene, dioxane, acetonitrile, methylene chloride or chloroform, at a temperature from about 25°C to about 150°C, preferably at about the reflux temperature, followed by heating in 85% phosphoric acid or an aqueous acid such as acetic acid, hydrochloric acid or sulfuric acid, preferably in 50-85% phosphoric acid.
  • Compounds of formula V-b may be prepared, as shown in Scheme 3, by heating the corresponding compounds of formula VI with excess of the appropriate compound of the formula R 3 CONH 2 .
  • Compounds of formula IV-d may be prepared, as shown in Scheme 4, by reacting compounds of formula IX with an appropriate reagent having the formula R 3 C(0)CHR 7 COO(C,-C 4 alkyl) in an R 3 COOH solvent at temperature from about 60 °C to about 180°C, preferably at about the reflux temperature.
  • Compounds of formula l-N may be prepared, as shown in Scheme 5, by reacting the corresponding compounds of formula X with a (C,-C 7 alkyl)nitrfte, with or without CuBr 2 , OuCI 2 , or Cul 2 , in an appropriate inert solvent such as acetonitrile, acetone, methylene chloride, chloroform, benzene or toluene, preferably acetonitrile at a temperature from about 25 °C to about 150°C, preferably from about 60° C to 100°C.
  • an appropriate inert solvent such as acetonitrile, acetone, methylene chloride, chloroform, benzene or toluene, preferably acetonitrile at a temperature from about 25 °C to about 150°C, preferably from about 60° C to 100°C.
  • Compounds of formula l-L and l-M may be prepared, as shown in Scheme 6, by reacting compounds of formula XI wherein X is S or O with a compound of the formula R 4 CH0 or R 4 CH(OC 1 -C 2 alkyl) 2 and an acid catalyst such as p-TsOH, HCl, HBr, H 2 S0 4 , or HCl, in toluene, xylene or benzene, preferably toluene, with from one to ten equivalents of water, at temperature from about 70°C to about 160°C, using a Dean-Stark trap or in the presence of anhydrous sodium sulfate.
  • an acid catalyst such as p-TsOH, HCl, HBr, H 2 S0 4 , or HCl
  • Compounds of formula I-K and I-U may be prepared by reacting the corresponding compounds of formula XI with triphosgene and thiophosgene, respectively, and a base such as triethylamine or pyridine in an appropriate inert solvent such as methylene chloride, THF, dioxane, ether, benzene or chloroform, preferably methylene chloride or dry THF, at temperature from about 0°C to about 25°C.
  • a base such as triethylamine or pyridine
  • an appropriate inert solvent such as methylene chloride, THF, dioxane, ether, benzene or chloroform, preferably methylene chloride or dry THF, at temperature from about 0°C to about 25°C.
  • Compounds of formula l-V, l-W, and l-X may be prepared, as illustrated in Scheme 7, starting from compounds of formula XII.
  • Compounds of formula XIII may be prepared by reacting the corresponding compounds of formula XII with hydroxylamine in acidic (e.g.. in trifluoroacetic acid) or basic (e.g.. in NaOAc or NaOH and hydroxylamine hydrochloride in a 0,-0 4 alcohol/water mixture) conditions at temperatures from about 25 °C to about 150°C, preferably at about the reflux temperature.
  • Compounds of formula XIV can be prepared by heating the corresponding compounds of formula XIII in acetic anhydride, trifluoroacetic anhydride or Tf 2 0, with or without a solvent such as acetic acid or methylene chloride, in the presence of an appropriate amine base such as triethylamine or pyridine.
  • Compounds of formula l-V, l-W and l-X may be prepared by heating the corresponding compounds of formula XIV and pyridine in an inert solvent such as DMF, DMSO, NMP, sulfolane or acetamide at a temperature from about 80 °C to about 180°C.
  • Compounds of formula l-G may be prepared, as illustrated in Scheme 8, by reducing the corresponding compounds of formula XVII. This reduction can be performed using standard methods known in literature for reduction of a nitro group to an amino group. Such methods include hydrogenation or reduction by iron in acetic acid. Cyclization may occur upon reduction or heating in an appropriate solvent such as a C,-C 4 alcohol, acetonitrile, toluene, THF, methylene chloride or acetic acid.
  • an appropriate solvent such as a C,-C 4 alcohol, acetonitrile, toluene, THF, methylene chloride or acetic acid.
  • the conversion of compounds of formula XVI into those of formula XVII can be accomplished using methods analogous to those described above for the conversion of compounds of formula V wherein W is cyano into compounds of formula I wherein B is a group having a carbon atom directly attached to the bicyclic ring.
  • the best method for conversion of a cyano group to a -COOH group is acid hydrolysis, for example, heating the cyano compound in 50-85% phosphoric acid or 50-90% acetic acid, preferably phosphoric acid.
  • the best method for converting a cyano group into a -00(0,-0 4 alkyl) is reacting the cyano compound with a Grignard reagent at a temperature from about 0°C to about 25 °C in ether, THF or dioxane.
  • the best method for converting a cyano group into a -CHO group is a diisobutylaluminum hydride reduction in THF, dioxane, or ether at a temperature from about -78°C to about 25°C, preferably from about -78 °C to about -40° C.
  • Compounds of the formula XVI may be prepared by reacting compounds of formula XV, wherein Hal is chloro, bromo or iodo, with a sodium, potassium, or lithium salt of R ⁇ CH 2 CN in an appropriate inert solvent such as toluene, benzene, a C,-C 5 alcohol, THF, DMSO, dioxane, or pyridine, with or without a Pd(ll) or Pd(0) catalyst, at a temperature from about -78°C to about 130°C.
  • an appropriate inert solvent such as toluene, benzene, a C,-C 5 alcohol, THF, DMSO, dioxane, or pyridine
  • Pd(ll) or Pd(0) catalyst at a temperature from about -78°C to about 130°C.
  • compounds of formula XVII may be prepared by subjecting compounds of the formula XV to halogen-metal exchange (e.g.. using an organo lithium agent such as tBuU, s-BuLi or BuLi at -78°C in ether, THF, or dioxane), followed by quenching with an electorphile such as R 5 CHO, to give compounds of formula XVIII.
  • halogen-metal exchange e.g.. using an organo lithium agent such as tBuU, s-BuLi or BuLi at -78°C in ether, THF, or dioxane
  • an electorphile such as R 5 CHO
  • the acid addition salts of compounds of the formula can be prepared in a conventional manner by treating a solution or suspension of the corresponding free base with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization techniques can be employed to isolate the salts.
  • suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene surfonic, p- toluenesulfojiic, and related acids.
  • the compounds of formula I and their pharmaceutically_acc ⁇ ptable salts may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses.
  • suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, oils (e.g.. sesame oil, peanut oil) and various organic solvents.
  • the pharmaceutical compositions formed by combining the novel compounds of formula I and pharmaceutically acceptable carriers can then be readily administered in a variety of dosage forms such as tablets, oil gel, powders, lozenges, syrups, injectable solutions and the like.
  • These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates, together with binding agents such as poiyvinylpyrrolidone, sucrose, gelatin and acacia.
  • disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates
  • binding agents such as poiyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium iauryl sulfate and talc are often useful for tabietting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols.
  • the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
  • solutions containing an active compound of this invention or a pharmaceutically acceptable salt thereof in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • the effective dosages for the active compounds of this invention will depend on the intended route of administration and factors such as the age and weight of the patient, as generally known to a physician.
  • the dosages will also depend on the particular illness to be treated. For instance, the daily dosage for stress-induced illnesses, inflammatory disorders, Alzheimer's disease, gastro-intestinal diseases, anorexia nervosa, hemorrhagic stress and drug and alcohol withdrawal symptoms will generally range from about 0.1 to about 50 mg/kg body weight of the patient to be treated.
  • Example 11-14 The title compounds of Examples 11-14 were prepared by the method analogous to that described in Example 10 starting from of 4-chloro-2-methyl-5- substituted-7-(substituted-phenyl)-5H-pyrrolo[3,2-d]pyrimidine or 7-chloro-5-methyl-1 - substituted-3-(substituted-phenyl)-1 H-pyrrolo(3,2-b]pyridine and an appropriate alcohol or thiol and a base.
  • PROCEDURE FOR EXAMPLES. 15 - 18 A mixture of 4-chloro-2-methyl-5-substituted-7-(subst ' ituted-phenyl)-5H- pyrrolo[3,2-d]pyrimidine or 7-bromo-1 ,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-1H- pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester (1 mmol) and an appropriate amine in DMSO (2 ml) was heated in 130°C oil bath until all the starting material was consumed. The mixture was quenched with water and extracted with ethyl acetate.
  • the chloroform layer was washed with brine, dried and concentrated to dryness to give 7-amino-1 ,5-dimethyl -3-(2,4,6-trimethyi- ph ⁇ nyl)-1 H-pyrrolo[3,2-b]pyridine-6-carboxylic acid methyl ester.
  • the product may be purified by trituration.

Abstract

L'invention concerne des composés de formule (I), dans laquelle les lignes pointillées représentent des doubles liaisons optionnelles; A est azote ou CR7; B est NR?1R2, CR1R2R10-C(=CR2R11)R1, NHCR1R2R10, OCR1R2R10, SCR1R2R10, CR2R10NHR1, CR2R10OR1, CR2R10SR1 ou COR2¿; J et K sont indépendamment azote ou carbone et ne sont pas en même temps azote; D et E sont choisis indépendamment entre azote, CR4, C=O, C=S, soufre, oxygène, CR?4R6 et NR8¿; G est azote ou carbone. Elle concerne également l'utilisation de ces composés pour prévenir ou inhiber un trouble pouvant être traité par antagonisation de la substance libératrice de la corticostimuline (CRF).
PCT/IB1997/000922 1996-08-28 1997-07-25 Derives 6,5-hetero-bicycliques substitues WO1998008847A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
JP51142998A JP3621706B2 (ja) 1996-08-28 1997-07-25 置換された６，５―ヘテロ―二環式誘導体
PL97332040A PL332040A1 (en) 1996-08-28 1997-07-25 Substitution 6,5-heterobicyclic derivatives
CA002263566A CA2263566C (fr) 1996-08-28 1997-07-25 Derives 6,5-hetero-bicycliques substitues
DE69736711T DE69736711T2 (de) 1996-08-28 1997-07-25 Substituierte 6,5-heterobicyclische-derivate
BR9711970A BR9711970A (pt) 1996-08-28 1997-07-25 Derivados 6,5-substitu¡do-heterobic¡clicos
IL12756697A IL127566A0 (en) 1996-08-28 1997-07-25 Substituted 6,5-hetero- bicyclic derivatives
AU34561/97A AU735401B2 (en) 1996-08-28 1997-07-25 Substituted 6,5-hetero-bicyclic derivatives
EA199900165A EA002769B1 (ru) 1996-08-28 1997-07-25 Замещенные 6,5-гетеробициклические производные
SK233-99A SK23399A3 (en) 1996-08-28 1997-07-25 6,5-hetero-bicyclic derivatives, use thereof and pharmaceutical composition on their base
EP97930697A EP0923582B1 (fr) 1996-08-28 1997-07-25 Derives 6,5-hetero-bicycliques substitues
HU9903965A HUP9903965A3 (en) 1996-08-28 1997-07-25 Substituted 6,5-hetero-bicyclic derivatives
NZ333302A NZ333302A (en) 1996-08-28 1997-07-25 Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor
IS4963A IS4963A (is) 1996-08-28 1999-01-29 Setnar 6,5-heteró-bísýklískar afleiður
BG103189A BG103189A (en) 1996-08-28 1999-02-22 Substituted 6,5-heterobicyclic derivatives
NO19990927A NO313636B1 (no) 1996-08-28 1999-02-26 Substituerte 6,5-hetero-bicykliske derivater, anvendelse derav samt farmasöytiske preparater
US10/160,206 US6900217B2 (en) 1996-08-28 2002-05-30 Substituted 6,5-hetero-bicyclic derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2503996P 1996-08-28 1996-08-28
US60/025,039 1996-08-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/242,682 Continuation US20010007867A1 (en) 1996-08-28 1997-07-25 Substituted 6,5-hetero-bicyclic derivatives

Publications (1)

Publication Number Publication Date
WO1998008847A1 true WO1998008847A1 (fr) 1998-03-05

Family

ID=21823717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1997/000922 WO1998008847A1 (fr) 1996-08-28 1997-07-25 Derives 6,5-hetero-bicycliques substitues

Country Status (36)

Country Link
EP (1) EP0923582B1 (fr)
JP (2) JP3621706B2 (fr)
KR (1) KR20000035934A (fr)
CN (1) CN1227554A (fr)
AP (1) AP762A (fr)
AR (1) AR015103A1 (fr)
AT (1) ATE340176T1 (fr)
AU (1) AU735401B2 (fr)
BG (1) BG103189A (fr)
BR (1) BR9711970A (fr)
CA (1) CA2263566C (fr)
CO (1) CO4600634A1 (fr)
CZ (1) CZ68199A3 (fr)
DE (1) DE69736711T2 (fr)
DZ (1) DZ2300A1 (fr)
EA (1) EA002769B1 (fr)
ES (1) ES2273369T3 (fr)
GT (1) GT199700095A (fr)
HR (1) HRP970454B1 (fr)
HU (1) HUP9903965A3 (fr)
ID (1) ID18249A (fr)
IL (1) IL127566A0 (fr)
IS (1) IS4963A (fr)
MA (1) MA26438A1 (fr)
NO (1) NO313636B1 (fr)
NZ (1) NZ333302A (fr)
OA (1) OA10977A (fr)
PA (1) PA8436201A1 (fr)
PE (1) PE108898A1 (fr)
PL (1) PL332040A1 (fr)
SK (1) SK23399A3 (fr)
TN (1) TNSN97145A1 (fr)
TR (1) TR199900389T2 (fr)
TW (1) TW575573B (fr)
WO (1) WO1998008847A1 (fr)
ZA (1) ZA977687B (fr)

Cited By (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035967A2 (fr) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et procedes associes
WO1998047903A1 (fr) * 1997-04-22 1998-10-29 Janssen Pharmaceutica N.V. Thiophenopyridines antagonistes du crf
WO1999001454A1 (fr) * 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Imidazopyrimidines et imidazopyridines utiles pour traiter des troubles neurologiques
WO1999040091A1 (fr) * 1998-02-06 1999-08-12 Amgen Inc. Composes et methodes permettant de moduler des conduites alimentaires et des pathologies y afferentes
WO1999051608A1 (fr) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company PYRIMIDINES ET PYRIDINES THIAZOLO[4,5-d] UTILISEES COMME ANTAGONISTES DU FACTEUR LIBERATEUR DE CORTICOTROPHINE (CRF)
WO1999064422A1 (fr) * 1998-06-09 1999-12-16 Neurogen Corporation Derives de pyrido[2, 3-b]indolizine et analogues aza associes; ligands crf1 specifiques
WO2000011003A1 (fr) * 1998-08-21 2000-03-02 Du Pont Pharmaceuticals Company Isoxazolo[4,5-d]pyrimidines comme antagonistes du crf
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
WO2000027846A2 (fr) * 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et methodes associees
WO2000027850A2 (fr) * 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et methodes associees
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
EP1040831A2 (fr) * 1999-04-02 2000-10-04 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
WO2000059908A2 (fr) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines antagonistes de corticoliberine (crf)
EP1082960A2 (fr) * 1999-08-27 2001-03-14 Pfizer Products Inc. Utilisation d'antagonistes du crf et compositions correspondantes pour traiter depression et pour modifier le rhytme circadien
WO2001025242A1 (fr) * 1999-10-01 2001-04-12 Astrazeneca Uk Limited Nouveaux composes de thiazolo(4,5-d)pyrimidine
WO2001042247A1 (fr) * 1999-12-13 2001-06-14 Eisai Co., Ltd. Composes heterotricycliques fusionnes, procede de preparation de ces composes et medicaments contenant ces composes
WO2001058907A1 (fr) * 2000-02-11 2001-08-16 Astrazeneca Ab Thiazolopyrimidines et leur utilisation comme modulateurs de l'activite du recepteur de chimiokine
WO2001058906A1 (fr) * 2000-02-11 2001-08-16 Astrazeneca Ab Composes pyrimidiniques et leur utilisation comme modulateurs de l"activite des recepteurs de chimiokine
WO2001058489A1 (fr) * 2000-02-14 2001-08-16 Japan Tobacco Inc. Agents prophylactiques/therapeutiques contre le stress postoperatoire
WO2001058902A1 (fr) * 2000-02-11 2001-08-16 Astrazeneca Ab Composes de pyrimide et leur utilisation comme modulateurs de l'activite du recepteur de chimiokine
US6281220B1 (en) 1995-05-12 2001-08-28 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US6291473B1 (en) 1998-04-02 2001-09-18 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino [2, 3-B] indole and 5,6,7,8-tetrahydro-9H-pyrimidino [4, 5-B] indole derivatives: CRF1 specific ligands
EP1149583A2 (fr) * 2000-04-13 2001-10-31 Pfizer Products Inc. Combinaison des antagonistes de la facteur de la liberation de la corticotropin et des secrétagogues de l hormone de croissance
EP1149835A1 (fr) * 1999-01-29 2001-10-31 Sumitomo Chemical Company Limited Agents inhibiteurs d'accumulation de graisse
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
WO2001087885A1 (fr) * 2000-05-18 2001-11-22 Neurocrine Biosciences, Inc. Antagonistes du recepteur de crf
WO2001087892A1 (fr) * 2000-05-18 2001-11-22 Neurocrine Biosciences, Inc. Antagonistes de recepteur crf
WO2002004453A2 (fr) * 2000-07-07 2002-01-17 Bristol-Myers Squibb Pharma Company Pyrrolo[3,4-d]pyrimidines comme antagonistes de la corticoliberine (crf)
US6358950B1 (en) 1996-07-24 2002-03-19 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
US6372743B1 (en) 1999-09-30 2002-04-16 Neurogen Corporation Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
WO2002088121A1 (fr) * 2001-04-27 2002-11-07 Eisai Co., Ltd. Pyrazolo[1,5-a] pyridines et medicaments les contenant
WO2002094826A1 (fr) * 2001-05-21 2002-11-28 Neurocrine Biosciences Inc. Derives tri- et tetraaza-acenaphthylene utilises comme antagonistes du recepteur crf
US6506762B1 (en) 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
US6509338B1 (en) 1998-06-22 2003-01-21 Bristol-Myers Squibb Company Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
EP1344779A1 (fr) * 1998-01-28 2003-09-17 Bristol-Myers Squibb Pharma Company Azolo-pyrimidines
WO2004035586A1 (fr) * 2002-10-17 2004-04-29 Pharmacia & Upjohn Company Llc Composes pyrrolo[1,2-b]pyridazine et leurs utilisations
US6777404B2 (en) 1999-10-29 2004-08-17 Pfizer Inc Use of corticotropin releasing factor antagonists and related compositions
JP2004530662A (ja) * 2001-03-13 2004-10-07 ブリストル−マイヤーズ スクイブ ファーマ カンパニー コルチコトロピン放出因子受容体リガンドとしての、４−（２−ブチルアミノ）−２，７−ジメチル−８−（２−メチル−６−メトキシピリド−３−イル）ピラゾロ−［１，５−ａ］−１，３，５−トリアジン、その鏡像異性体および薬学的に許容できる塩類
WO2004087708A1 (fr) * 2003-04-04 2004-10-14 Pharmacia & Upjohn Company Llc Composes de pyrrolo (1,2-b) pyridazine et leur utilisation comme antagonistes du recepteur de corticoliberine-1
WO2004087710A1 (fr) * 2003-04-02 2004-10-14 Pharmacia & Upjohn Company Llc Composes de pyrrolo[1,2-b]pyridazine et leur utilisation comme antagonistes des recepteurs du crf1
WO2004087709A1 (fr) * 2003-04-04 2004-10-14 Pharmacia & Upjohn Company Llc Composes de pyrrolo[1,2-b]pyridazine et leurs utilisations
WO2004092176A1 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Composes de pyrrolo[1,2-b]pyridazine et leurs utilisations
WO2004099213A2 (fr) * 2003-05-07 2004-11-18 Pharmacia & Upjohn Company Llc Composes pyrrolo[1,2-b]pyridaziniques
WO2005007658A2 (fr) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Derives aryle et heteroaryle condenses utilises comme modulateurs du metabolisme et prophylaxie et traitement des troubles metaboliques
US6908916B2 (en) 2001-11-14 2005-06-21 Bristol Myers Squibb Company C-5 modified indazolylpyrrolotriazines
US6916815B2 (en) 2002-12-13 2005-07-12 Bristol-Myers Squibb Company C-6 modified indazolylpyrrolotriazines
WO2005066142A2 (fr) * 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Derives de pyrrolopyrimidine et de pyrrolotriazine
US6943174B2 (en) 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
JP2005527565A (ja) * 2002-03-28 2005-09-15 ウスタフ エクスペリメンタルニ ボタニキ エーブイ シーアール （インスティチュート オブ エクスペリメンタル ボタニー アカデミー オブ サイエンシーズ オブ ザ チェコ リパブリック） 新しいピラゾロ［４，３−ｄ］ピリミジン、その調整方法、及び治療方法
US6949643B2 (en) 2001-04-12 2005-09-27 Astrazeneca Ab Thiazolopytimidines and their use as modulators of chemokine receptor activity
US6960583B2 (en) 1999-04-06 2005-11-01 Bristol-Myers Squibb Company Pyrazolotriazines as CRF antagonists
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2006044958A1 (fr) 2004-10-19 2006-04-27 Sb Pharmco Puerto Rico Inc. Derives de pyrazolo[1,5-alpha]pyrimidinyle utiles comme antagonistes vis-a-vis du recepteur du facteur de liberation de la corticotropine (crf)
EP1669071A1 (fr) * 1999-05-21 2006-06-14 Bristol-Myers Squibb Company Pyrrolotriazines comme inhibiteurs des kinases.
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
US7071193B2 (en) 2000-10-20 2006-07-04 Astrazeneca Ab 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases
US7078405B2 (en) 2001-02-08 2006-07-18 Eisai Co., Ltd. Imidazo[1,2-b]pyridazine compound
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7141571B2 (en) 2003-12-29 2006-11-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds as kinase inhibitors
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7153961B2 (en) 2003-11-25 2006-12-26 Bristol-Myers Squibb Pharma Co. Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
US7157486B2 (en) 2001-07-25 2007-01-02 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2007004749A1 (fr) 2005-07-05 2007-01-11 Takeda Pharmaceutical Company Limited Dérivés hétérocycliques fondus et leur utilisation
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7211666B2 (en) 2000-11-17 2007-05-01 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US7247626B2 (en) 2002-03-07 2007-07-24 Smithkline Beecham Corporation Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them
US7253284B2 (en) 2001-07-17 2007-08-07 Giaxo Group Limited Chemical compounds
US7262192B2 (en) 2003-04-29 2007-08-28 Pfizer Inc. Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors
EP1832590A2 (fr) 2000-12-28 2007-09-12 Ono Pharmaceutical Co., Ltd. Composés tri-hétérocycliques et produit pharmaceutique comprenant ceux-ci en tant quýingrédient actif
US7323569B2 (en) 2002-10-22 2008-01-29 Eisai R&D Management Co., Ltd. 7-phenylpyrazolopyridine compounds
WO2008036579A1 (fr) 2006-09-20 2008-03-27 Eli Lilly And Company Thiazole pyrazolopyrimidines convenant comme antagonistes du récepteur du crf1
EP1928879A2 (fr) 2005-09-22 2008-06-11 Brystol-Myers Squibb Company Composes heterocycliques condenses utilises comme modulateurs des kinases
US7427630B2 (en) 2003-04-09 2008-09-23 Sb Pharmaco Puerto Rico Inc. Condensed N-heterocyclic compounds and their use as CRF receptor antagonists
US7429571B2 (en) 2004-10-29 2008-09-30 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7514410B2 (en) 2005-03-29 2009-04-07 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
US7557111B2 (en) 2004-01-06 2009-07-07 Taisho Pharmaceutical Co., Ltd. Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
US7579342B2 (en) 2000-02-23 2009-08-25 Astrazeneca Pteridine compounds for the treatment of psoriasis
US7585867B2 (en) 2002-09-20 2009-09-08 Astrazeneca Ab Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one
US7589097B2 (en) 2001-01-10 2009-09-15 Vernalis Research Limited Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
US7737154B2 (en) 2003-12-22 2010-06-15 Smithkline Beecham (Cork) Limited CRF receptor antagonists and methods relating thereto
US7790883B2 (en) 2003-12-05 2010-09-07 Astrazeneca Ab Process for the preparation of thiazolopyrimidines
US7879851B2 (en) 2004-02-20 2011-02-01 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
WO2011101644A1 (fr) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de kinases
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
US8110580B2 (en) 2006-09-20 2012-02-07 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
WO2012032031A1 (fr) 2010-09-10 2012-03-15 Bayer Pharma Aktiengesellschaft Imidazopyridazines substituées
WO2012080229A1 (fr) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
WO2012080232A1 (fr) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines 2-substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
WO2012080234A1 (fr) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-imidazopyrazines substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
US8252795B2 (en) 2008-10-09 2012-08-28 Bristol-Myers Squibb Company Imidazopyridazinecarbonitriles useful as kinase inhibitors
WO2012149157A2 (fr) * 2011-04-26 2012-11-01 Bioenergenix Composés hétérocycliques pour l'inhibition de pask
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
US8394823B2 (en) 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
US8431603B2 (en) 2008-04-15 2013-04-30 Eisai R&D Management Co., Ltd. 3-phenylpyrazolo[5,1-b]thiazole compounds
US8450328B2 (en) 2008-06-25 2013-05-28 Vernalis (R&D) Limited Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists
US8530504B2 (en) 2009-10-08 2013-09-10 Eisai R&D Management Co., Ltd. Pyrazolothiazole compound
WO2013135612A1 (fr) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Imidazopyridazines substituées
WO2014020041A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8937064B2 (en) 2007-12-19 2015-01-20 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors
US8969586B2 (en) 2011-09-27 2015-03-03 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
US9145419B2 (en) 2010-04-28 2015-09-29 Bristol-Myers Squibb Company Imidazopyridazinyl compounds
WO2015165428A1 (fr) * 2014-04-30 2015-11-05 Masarykova Univerzita Furopyridines utilisées en tant qu'inhibiteurs de protéine kinases
US9266880B2 (en) 2010-11-12 2016-02-23 Bristol-Myers Squibb Company Substituted azaindazole compounds
US9586958B2 (en) 2013-06-11 2017-03-07 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
US10253003B2 (en) 2012-11-16 2019-04-09 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
US10259793B2 (en) 2013-02-21 2019-04-16 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
US10259814B2 (en) 2012-10-10 2019-04-16 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US10266543B2 (en) 2013-03-29 2019-04-23 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
US10272085B2 (en) 2011-04-08 2019-04-30 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US10280180B2 (en) 2012-07-13 2019-05-07 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
US10280167B2 (en) 2011-11-09 2019-05-07 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
US10316043B2 (en) 2013-07-30 2019-06-11 Janssen Sciences Ireland Unlimited Company Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
US10377738B2 (en) 2013-05-24 2019-08-13 Janssen Sciences Ireland Unlimited Company Pyridone derivatives for the treatment of viral infections and further diseases
US10385054B2 (en) 2013-06-27 2019-08-20 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US10968184B2 (en) 2016-09-29 2021-04-06 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11053256B2 (en) 2016-07-01 2021-07-06 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
US11191765B2 (en) 2012-10-25 2021-12-07 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
US11597704B2 (en) 2018-03-01 2023-03-07 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
US11858932B2 (en) 2020-08-12 2024-01-02 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004110454A1 (fr) * 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. Composition de traitement ou de prevention de maladies necessitant l'administration d'un agoniste du recepteur a2a de l'adenosine
EP1680424A2 (fr) * 2003-09-05 2006-07-19 Neurogen Corporation Pyridines, pyrazines et pyrimidines fusionnees avec heteroaryle utilisees comme ligands de recepteurs crf1
US20090234117A1 (en) * 2005-05-27 2009-09-17 Toshihiko Kashiwagi Pyrazolopyrimidine Derivative
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CA2794861A1 (fr) * 2010-04-16 2011-10-20 Abbvie Inc. Inhibiteurs de kinases de type pyrrolopyrazinone
ES2607184T3 (es) * 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
RU2699568C2 (ru) * 2015-12-21 2019-09-06 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Лиганды транслокаторного белка TSPO, обладающие антидепрессивной и ноотропной активностью
CN108812546A (zh) * 2018-09-07 2018-11-16 四川省草原科学研究院 适于青藏高原地区牦牛运输减少应激的药物及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033750A1 (fr) * 1994-06-08 1995-12-14 Pfizer Inc. Antagonistes du facteur liberant la corticotrophine
WO1996035689A1 (fr) * 1995-05-12 1996-11-14 Neurogen Corporation Derives nouveaux de deazapurine; une nouvelle classe de ligands specifiques de crf1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033750A1 (fr) * 1994-06-08 1995-12-14 Pfizer Inc. Antagonistes du facteur liberant la corticotrophine
WO1996035689A1 (fr) * 1995-05-12 1996-11-14 Neurogen Corporation Derives nouveaux de deazapurine; une nouvelle classe de ligands specifiques de crf1

Cited By (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281220B1 (en) 1995-05-12 2001-08-28 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US6358950B1 (en) 1996-07-24 2002-03-19 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
US6136809A (en) * 1996-07-24 2000-10-24 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US7678793B2 (en) 1996-07-24 2010-03-16 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
WO1998035967A2 (fr) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et procedes associes
WO1998035967A3 (fr) * 1997-02-18 1998-12-10 Neurocrine Biosciences Inc Antagonistes de recepteurs du crf et procedes associes
US6974808B2 (en) 1997-02-18 2005-12-13 Bristol-Myers Squibb Company CRF receptor antagonists and methods relating thereto
WO1998047903A1 (fr) * 1997-04-22 1998-10-29 Janssen Pharmaceutica N.V. Thiophenopyridines antagonistes du crf
US6211195B1 (en) 1997-04-22 2001-04-03 Neurocrine Biosciences, Inc. CRF antagonistic thiophenopyridines
US6143743A (en) * 1997-07-03 2000-11-07 Dupont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6362180B1 (en) 1997-07-03 2002-03-26 Bristol-Myers Squibb Pharma Company Imidazopyridines for the treatment of neurological disorders
WO1999001454A1 (fr) * 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Imidazopyrimidines et imidazopyridines utiles pour traiter des troubles neurologiques
US6642230B2 (en) 1997-07-03 2003-11-04 Bristol-Myers Squibb Pharma Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
EP1344779A1 (fr) * 1998-01-28 2003-09-17 Bristol-Myers Squibb Pharma Company Azolo-pyrimidines
US6583154B1 (en) 1998-02-06 2003-06-24 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO1999040091A1 (fr) * 1998-02-06 1999-08-12 Amgen Inc. Composes et methodes permettant de moduler des conduites alimentaires et des pathologies y afferentes
US6291473B1 (en) 1998-04-02 2001-09-18 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino [2, 3-B] indole and 5,6,7,8-tetrahydro-9H-pyrimidino [4, 5-B] indole derivatives: CRF1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US6107294A (en) * 1998-04-03 2000-08-22 Dupont Pharmaceuticals Thiazolo[4,5-d]pyrimidines and pyridines as corticotropin releasing factor (CRF) antagonists
WO1999051608A1 (fr) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company PYRIMIDINES ET PYRIDINES THIAZOLO[4,5-d] UTILISEES COMME ANTAGONISTES DU FACTEUR LIBERATEUR DE CORTICOTROPHINE (CRF)
US6495686B2 (en) 1998-06-09 2002-12-17 Neurogen Corporation Pyrimido [4,5,b]indolizine derivatives and aza analogues thereof; CRF1 specific ligands
WO1999064422A1 (fr) * 1998-06-09 1999-12-16 Neurogen Corporation Derives de pyrido[2, 3-b]indolizine et analogues aza associes; ligands crf1 specifiques
US6194574B1 (en) 1998-06-09 2001-02-27 Neurogen Corporation Pyrido[2,3-b]indolizine derivatives and aza analogues thereof: CRF1 specific ligands
US6509338B1 (en) 1998-06-22 2003-01-21 Bristol-Myers Squibb Company Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
WO2000011003A1 (fr) * 1998-08-21 2000-03-02 Du Pont Pharmaceuticals Company Isoxazolo[4,5-d]pyrimidines comme antagonistes du crf
US6589958B1 (en) 1998-08-21 2003-07-08 Bristol-Myers Squibb Pharma Company Isoxazolo [4,5-d] pyrimidines as CRF antagonists
US6294671B1 (en) * 1998-08-21 2001-09-25 Dupont Pharmaceuticals Company Isoxazolo[4, 5-D]pyrimidines as CRF antagonists
WO2000027850A3 (fr) * 1998-11-12 2000-08-03 Neurocrine Biosciences Inc Antagonistes de recepteurs du crf et methodes associees
JP2002529465A (ja) * 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびｃｒｆレセプターアンタゴニストに関する方法
JP2002529469A (ja) * 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関する方法
US6514982B1 (en) 1998-11-12 2003-02-04 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6723721B2 (en) 1998-11-12 2004-04-20 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO2000027846A3 (fr) * 1998-11-12 2000-11-16 Neurocrine Biosciences Inc Antagonistes de recepteurs du crf et methodes associees
WO2000027846A2 (fr) * 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et methodes associees
US6348466B1 (en) 1998-11-12 2002-02-19 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO2000027850A2 (fr) * 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et methodes associees
EP1149835A4 (fr) * 1999-01-29 2002-08-21 Sumitomo Chemical Co Agents inhibiteurs d'accumulation de graisse
EP1149835A1 (fr) * 1999-01-29 2001-10-31 Sumitomo Chemical Company Limited Agents inhibiteurs d'accumulation de graisse
EP1040831A3 (fr) * 1999-04-02 2003-05-02 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
EP1040831A2 (fr) * 1999-04-02 2000-10-04 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
US6960583B2 (en) 1999-04-06 2005-11-01 Bristol-Myers Squibb Company Pyrazolotriazines as CRF antagonists
WO2000059908A2 (fr) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines antagonistes de corticoliberine (crf)
WO2000059908A3 (fr) * 1999-04-06 2002-08-22 Du Pont Pharm Co Pyrazolopyrimidines antagonistes de corticoliberine (crf)
US6958341B2 (en) 1999-04-06 2005-10-25 Bristol-Myers Squibb Pharma Company Pyrazolopyrimidines as CRF antagonists
US7026317B2 (en) 1999-04-06 2006-04-11 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as CRF antagonists
EP1669071A1 (fr) * 1999-05-21 2006-06-14 Bristol-Myers Squibb Company Pyrrolotriazines comme inhibiteurs des kinases.
US7112675B2 (en) 1999-05-21 2006-09-26 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
EP1082960A2 (fr) * 1999-08-27 2001-03-14 Pfizer Products Inc. Utilisation d'antagonistes du crf et compositions correspondantes pour traiter depression et pour modifier le rhytme circadien
US6372743B1 (en) 1999-09-30 2002-04-16 Neurogen Corporation Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
US7074929B2 (en) 1999-09-30 2006-07-11 Neurogen Corp. Certain alkylene diamine-substituted heterocycles
US6506762B1 (en) 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
US6696445B2 (en) 1999-09-30 2004-02-24 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
EP1348709A3 (fr) * 1999-10-01 2003-11-19 AstraZeneca UK Limited Composés de thiazolo[4,5-d]pyrimidine
US6790850B1 (en) 1999-10-01 2004-09-14 Astrazeneca Uk Limited Thiazolo(4,5-d)pyrimidine compounds
EP1348709A2 (fr) * 1999-10-01 2003-10-01 AstraZeneca UK Limited Composés de thiazolo[4,5-d]pyrimidine
KR100765051B1 (ko) * 1999-10-01 2007-10-09 아스트라제네카 유케이 리미티드 신규 티아졸로(4,5-ｄ)피리미딘 화합물
WO2001025242A1 (fr) * 1999-10-01 2001-04-12 Astrazeneca Uk Limited Nouveaux composes de thiazolo(4,5-d)pyrimidine
US8143261B2 (en) 1999-10-01 2012-03-27 Astrazeneca Ab Thiazolo (4,5-D) pyrimidine compounds
US6777404B2 (en) 1999-10-29 2004-08-17 Pfizer Inc Use of corticotropin releasing factor antagonists and related compositions
US6927221B2 (en) 1999-12-13 2005-08-09 Eisai Co., Ltd. Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
US6951865B2 (en) 1999-12-13 2005-10-04 Eisai Co., Ltd. Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same
US6995163B2 (en) 1999-12-13 2006-02-07 Eisai Co., Ltd. Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
WO2001042247A1 (fr) * 1999-12-13 2001-06-14 Eisai Co., Ltd. Composes heterotricycliques fusionnes, procede de preparation de ces composes et medicaments contenant ces composes
WO2001058906A1 (fr) * 2000-02-11 2001-08-16 Astrazeneca Ab Composes pyrimidiniques et leur utilisation comme modulateurs de l"activite des recepteurs de chimiokine
WO2001058907A1 (fr) * 2000-02-11 2001-08-16 Astrazeneca Ab Thiazolopyrimidines et leur utilisation comme modulateurs de l'activite du recepteur de chimiokine
US6958343B2 (en) 2000-02-11 2005-10-25 Astrazeneca, Ab Thiazolopyrimidines and their use as modulators of chemokine receptor activity
US6958344B2 (en) 2000-02-11 2005-10-25 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
WO2001058902A1 (fr) * 2000-02-11 2001-08-16 Astrazeneca Ab Composes de pyrimide et leur utilisation comme modulateurs de l'activite du recepteur de chimiokine
WO2001058489A1 (fr) * 2000-02-14 2001-08-16 Japan Tobacco Inc. Agents prophylactiques/therapeutiques contre le stress postoperatoire
US7579342B2 (en) 2000-02-23 2009-08-25 Astrazeneca Pteridine compounds for the treatment of psoriasis
EP1149583A3 (fr) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinaison des antagonistes de la facteur de la liberation de la corticotropin et des secrétagogues de l hormone de croissance
EP1149583A2 (fr) * 2000-04-13 2001-10-31 Pfizer Products Inc. Combinaison des antagonistes de la facteur de la liberation de la corticotropin et des secrétagogues de l hormone de croissance
WO2001087885A1 (fr) * 2000-05-18 2001-11-22 Neurocrine Biosciences, Inc. Antagonistes du recepteur de crf
WO2001087892A1 (fr) * 2000-05-18 2001-11-22 Neurocrine Biosciences, Inc. Antagonistes de recepteur crf
US6440960B1 (en) 2000-05-18 2002-08-27 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6943174B2 (en) 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
US6734185B2 (en) 2000-07-07 2004-05-11 Bristol-Myers Squibb Pharma Company Pyrrolo[3,4-d]pyrimidines as corticotropin releasing factor (CRF) antagonists
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
WO2002004453A2 (fr) * 2000-07-07 2002-01-17 Bristol-Myers Squibb Pharma Company Pyrrolo[3,4-d]pyrimidines comme antagonistes de la corticoliberine (crf)
WO2002004453A3 (fr) * 2000-07-07 2002-06-13 Du Pont Pharm Co Pyrrolo[3,4-d]pyrimidines comme antagonistes de la corticoliberine (crf)
US7071193B2 (en) 2000-10-20 2006-07-04 Astrazeneca Ab 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases
US7211666B2 (en) 2000-11-17 2007-05-01 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
EP1832590A2 (fr) 2000-12-28 2007-09-12 Ono Pharmaceutical Co., Ltd. Composés tri-hétérocycliques et produit pharmaceutique comprenant ceux-ci en tant quýingrédient actif
US7589097B2 (en) 2001-01-10 2009-09-15 Vernalis Research Limited Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists
CZ301916B6 (cs) * 2001-01-10 2010-07-28 Vernalis Research Limited Použití triazolo[4,5-d]pyrimidinové slouceniny, farmaceutický prostredek a triazolo[4,5-d]pyrimidinová sloucenina
US7078405B2 (en) 2001-02-08 2006-07-18 Eisai Co., Ltd. Imidazo[1,2-b]pyridazine compound
US7772249B2 (en) 2001-02-08 2010-08-10 Eisai R&D Management Co., Ltd. Imidazo[1,2-b]pyridazine compound
JP2004530662A (ja) * 2001-03-13 2004-10-07 ブリストル−マイヤーズ スクイブ ファーマ カンパニー コルチコトロピン放出因子受容体リガンドとしての、４−（２−ブチルアミノ）−２，７−ジメチル−８−（２−メチル−６−メトキシピリド−３−イル）ピラゾロ−［１，５−ａ］−１，３，５−トリアジン、その鏡像異性体および薬学的に許容できる塩類
US6949643B2 (en) 2001-04-12 2005-09-27 Astrazeneca Ab Thiazolopytimidines and their use as modulators of chemokine receptor activity
US7091215B2 (en) 2001-04-27 2006-08-15 Eisai Co., Ltd. Pyrazolo[1,5-a]pyridines and medicines containing the same
US7625925B2 (en) 2001-04-27 2009-12-01 Eisai R&D Management Co., Ltd Pyrazolo[1,5-a]pyridines and medicines containing the same
CZ301491B6 (cs) * 2001-04-27 2010-03-24 Eisai R&D Management Co., Ltd. Pyrazolo[1,5-a]pyridiny a léciva s jejich obsahem
WO2002088121A1 (fr) * 2001-04-27 2002-11-07 Eisai Co., Ltd. Pyrazolo[1,5-a] pyridines et medicaments les contenant
US7285666B2 (en) 2001-04-27 2007-10-23 Eisai R&D Management Co., Ltd. Pyrazolo[1,5-a] pyridines and medicines containing the same
US7446108B2 (en) 2001-05-21 2008-11-04 Neurocrine, Inc. Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists
WO2002094826A1 (fr) * 2001-05-21 2002-11-28 Neurocrine Biosciences Inc. Derives tri- et tetraaza-acenaphthylene utilises comme antagonistes du recepteur crf
US7253284B2 (en) 2001-07-17 2007-08-07 Giaxo Group Limited Chemical compounds
US7157486B2 (en) 2001-07-25 2007-01-02 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US7803944B2 (en) 2001-07-25 2010-09-28 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US6908916B2 (en) 2001-11-14 2005-06-21 Bristol Myers Squibb Company C-5 modified indazolylpyrrolotriazines
US7247626B2 (en) 2002-03-07 2007-07-24 Smithkline Beecham Corporation Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them
JP2005527565A (ja) * 2002-03-28 2005-09-15 ウスタフ エクスペリメンタルニ ボタニキ エーブイ シーアール （インスティチュート オブ エクスペリメンタル ボタニー アカデミー オブ サイエンシーズ オブ ザ チェコ リパブリック） 新しいピラゾロ［４，３−ｄ］ピリミジン、その調整方法、及び治療方法
US7585867B2 (en) 2002-09-20 2009-09-08 Astrazeneca Ab Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one
US7074791B2 (en) 2002-10-17 2006-07-11 Pfizer Inc. Pyrrolo[1,2-b]pyridazine compounds and their uses
WO2004035586A1 (fr) * 2002-10-17 2004-04-29 Pharmacia & Upjohn Company Llc Composes pyrrolo[1,2-b]pyridazine et leurs utilisations
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7323569B2 (en) 2002-10-22 2008-01-29 Eisai R&D Management Co., Ltd. 7-phenylpyrazolopyridine compounds
US6916815B2 (en) 2002-12-13 2005-07-12 Bristol-Myers Squibb Company C-6 modified indazolylpyrrolotriazines
US7148220B2 (en) 2002-12-13 2006-12-12 Bristol-Myers Squibb Company C-6 modified indazolylpyrrolotriazines
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2004087710A1 (fr) * 2003-04-02 2004-10-14 Pharmacia & Upjohn Company Llc Composes de pyrrolo[1,2-b]pyridazine et leur utilisation comme antagonistes des recepteurs du crf1
US7041671B2 (en) 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
WO2004087709A1 (fr) * 2003-04-04 2004-10-14 Pharmacia & Upjohn Company Llc Composes de pyrrolo[1,2-b]pyridazine et leurs utilisations
US7056920B2 (en) 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
WO2004087708A1 (fr) * 2003-04-04 2004-10-14 Pharmacia & Upjohn Company Llc Composes de pyrrolo (1,2-b) pyridazine et leur utilisation comme antagonistes du recepteur de corticoliberine-1
US7034023B2 (en) 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7427630B2 (en) 2003-04-09 2008-09-23 Sb Pharmaco Puerto Rico Inc. Condensed N-heterocyclic compounds and their use as CRF receptor antagonists
WO2004092176A1 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Composes de pyrrolo[1,2-b]pyridazine et leurs utilisations
US7262192B2 (en) 2003-04-29 2007-08-28 Pfizer Inc. Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors
WO2004099213A2 (fr) * 2003-05-07 2004-11-18 Pharmacia & Upjohn Company Llc Composes pyrrolo[1,2-b]pyridaziniques
WO2004099213A3 (fr) * 2003-05-07 2005-04-28 Pharmacia & Upjohn Co Llc Composes pyrrolo[1,2-b]pyridaziniques
WO2005007658A2 (fr) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Derives aryle et heteroaryle condenses utilises comme modulateurs du metabolisme et prophylaxie et traitement des troubles metaboliques
WO2005007658A3 (fr) * 2003-07-14 2005-06-16 Arena Pharm Inc Derives aryle et heteroaryle condenses utilises comme modulateurs du metabolisme et prophylaxie et traitement des troubles metaboliques
US7625906B2 (en) 2003-07-14 2009-12-01 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP2287165A2 (fr) 2003-07-14 2011-02-23 Arena Pharmaceuticals, Inc. Dérivés d'hétéroaryle et aryle fusionné en tant que modulateurs du métabolisme et prophylaxie et traitement des troubles associés
EP2287166A3 (fr) * 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Dérivés d'hétéroaryle et aryle fusionné en tant que modulateurs du métabolisme et prophylaxie et traitement des troubles associés
EP2287165A3 (fr) * 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Dérivés d'hétéroaryle et aryle fusionné en tant que modulateurs du métabolisme et prophylaxie et traitement des troubles associés
EP2292620A2 (fr) 2003-07-14 2011-03-09 Arena Pharmaceuticals, Inc. Dérivés d'hétéroaryle et aryle fusionné en tant que modulateurs du métabolisme et prophylaxie et traitement des troubles associés
EA010023B1 (ru) * 2003-07-14 2008-06-30 Арена Фармасьютикалз, Инк. Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7132426B2 (en) * 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP2287166A2 (fr) 2003-07-14 2011-02-23 Arena Pharmaceuticals, Inc. Dérivés d'hétéroaryle et aryle fusionné en tant que modulateurs du métabolisme et prophylaxie et traitement des troubles associés
US7153961B2 (en) 2003-11-25 2006-12-26 Bristol-Myers Squibb Pharma Co. Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
US7442792B2 (en) 2003-11-25 2008-10-28 Bristol-Myers Squibb Pharma Company Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7790883B2 (en) 2003-12-05 2010-09-07 Astrazeneca Ab Process for the preparation of thiazolopyrimidines
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7737154B2 (en) 2003-12-22 2010-06-15 Smithkline Beecham (Cork) Limited CRF receptor antagonists and methods relating thereto
US7141571B2 (en) 2003-12-29 2006-11-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
US7297695B2 (en) 2003-12-29 2007-11-20 Bristol-Myers Squibb Company Pyrrolotriazine compounds as kinase inhibitors
US7846931B2 (en) 2003-12-29 2010-12-07 Bristol-Myers Squibb Company Pyrrolotriazine compounds as kinase inhibitors
WO2005066142A3 (fr) * 2004-01-06 2005-10-13 Taisho Pharmaceutical Co Ltd Derives de pyrrolopyrimidine et de pyrrolotriazine
JP2007517794A (ja) * 2004-01-06 2007-07-05 大正製薬株式会社 ピロロピリミジン及びピロロトリアジン誘導体
US7557111B2 (en) 2004-01-06 2009-07-07 Taisho Pharmaceutical Co., Ltd. Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
JP4742273B2 (ja) * 2004-01-06 2011-08-10 大正製薬株式会社 ピロロピリミジン及びピロロトリアジン誘導体
US8106194B2 (en) 2004-01-06 2012-01-31 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolotriazine derivatives
WO2005066142A2 (fr) * 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Derives de pyrrolopyrimidine et de pyrrolotriazine
US7879851B2 (en) 2004-02-20 2011-02-01 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8030309B2 (en) 2004-02-20 2011-10-04 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
WO2006044958A1 (fr) 2004-10-19 2006-04-27 Sb Pharmco Puerto Rico Inc. Derives de pyrazolo[1,5-alpha]pyrimidinyle utiles comme antagonistes vis-a-vis du recepteur du facteur de liberation de la corticotropine (crf)
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
US7879862B2 (en) 2004-10-19 2011-02-01 Smithkline Beecham (Cork) Limited Pyrazolo[1,5-alpha]pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US8133870B2 (en) 2004-10-29 2012-03-13 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
US7429571B2 (en) 2004-10-29 2008-09-30 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
US8163703B2 (en) 2005-03-29 2012-04-24 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
US7514410B2 (en) 2005-03-29 2009-04-07 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
WO2007004749A1 (fr) 2005-07-05 2007-01-11 Takeda Pharmaceutical Company Limited Dérivés hétérocycliques fondus et leur utilisation
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
EP1928879A2 (fr) 2005-09-22 2008-06-11 Brystol-Myers Squibb Company Composes heterocycliques condenses utilises comme modulateurs des kinases
EP1928879B1 (fr) * 2005-09-22 2013-02-13 Bristol-Myers Squibb Company Composes heterocycliques condenses utilises comme modulateurs des kinases
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
TWI402269B (zh) * 2006-09-20 2013-07-21 Lilly Co Eli 噻唑吡唑并嘧啶化合物
US8110580B2 (en) 2006-09-20 2012-02-07 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
WO2008036579A1 (fr) 2006-09-20 2008-03-27 Eli Lilly And Company Thiazole pyrazolopyrimidines convenant comme antagonistes du récepteur du crf1
US8030304B2 (en) 2006-09-20 2011-10-04 Eli Lilly And Company Thiazole pyrazolopyrimidines CRF1 receptor antagonists
US8937064B2 (en) 2007-12-19 2015-01-20 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors
US8394823B2 (en) 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
US8431603B2 (en) 2008-04-15 2013-04-30 Eisai R&D Management Co., Ltd. 3-phenylpyrazolo[5,1-b]thiazole compounds
US8450328B2 (en) 2008-06-25 2013-05-28 Vernalis (R&D) Limited Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists
US9765080B2 (en) 2008-06-25 2017-09-19 Vernalis (R&D) Limited Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US10875868B2 (en) 2008-06-25 2020-12-29 Vernalis (R&D) Limited Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
US8987279B2 (en) 2008-06-25 2015-03-24 Vernalis (R&D) Limited Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists
US9376443B2 (en) 2008-06-25 2016-06-28 Vernalis (R&D) Limited Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US11466019B2 (en) 2008-06-25 2022-10-11 Vernalis (R&D) Limited Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
US10538526B2 (en) 2008-06-25 2020-01-21 Vernalis (R&D) Limited Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US10106547B2 (en) 2008-06-25 2018-10-23 Vernalis (R&D) Limited Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US8252795B2 (en) 2008-10-09 2012-08-28 Bristol-Myers Squibb Company Imidazopyridazinecarbonitriles useful as kinase inhibitors
US9371328B2 (en) 2008-10-09 2016-06-21 Bristol-Myers Squibb Company Imidazopyridazinecarbonitriles useful as kinase inhibitors
US8530504B2 (en) 2009-10-08 2013-09-10 Eisai R&D Management Co., Ltd. Pyrazolothiazole compound
WO2011101644A1 (fr) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de kinases
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US9145419B2 (en) 2010-04-28 2015-09-29 Bristol-Myers Squibb Company Imidazopyridazinyl compounds
US9255100B2 (en) 2010-09-10 2016-02-09 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
WO2012032031A1 (fr) 2010-09-10 2012-03-15 Bayer Pharma Aktiengesellschaft Imidazopyridazines substituées
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US9266880B2 (en) 2010-11-12 2016-02-23 Bristol-Myers Squibb Company Substituted azaindazole compounds
WO2012080229A1 (fr) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
WO2012080232A1 (fr) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines 2-substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
WO2012080234A1 (fr) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-imidazopyrazines substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
US10420767B2 (en) 2011-04-08 2019-09-24 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US10780089B2 (en) 2011-04-08 2020-09-22 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US10272085B2 (en) 2011-04-08 2019-04-30 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US11541050B2 (en) 2011-04-08 2023-01-03 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
WO2012149157A2 (fr) * 2011-04-26 2012-11-01 Bioenergenix Composés hétérocycliques pour l'inhibition de pask
WO2012149157A3 (fr) * 2011-04-26 2013-02-28 Bioenergenix Composés hétérocycliques pour l'inhibition de pask
US9598436B2 (en) 2011-09-27 2017-03-21 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
US9242967B2 (en) 2011-09-27 2016-01-26 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
US8969586B2 (en) 2011-09-27 2015-03-03 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
US11104678B2 (en) 2011-11-09 2021-08-31 Janssen Sciences Ireland Unlimited Company Purine derivatives for the treatment of viral infections
US10280167B2 (en) 2011-11-09 2019-05-07 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
WO2013135612A1 (fr) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Imidazopyridazines substituées
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US10822349B2 (en) 2012-07-13 2020-11-03 Janssen Sciences Ireland Unlimited Company Macrocyclic purines for the treatment of viral infections
US10280180B2 (en) 2012-07-13 2019-05-07 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
WO2014020041A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
US10259814B2 (en) 2012-10-10 2019-04-16 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US11220504B2 (en) 2012-10-10 2022-01-11 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
US11191765B2 (en) 2012-10-25 2021-12-07 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
US10253003B2 (en) 2012-11-16 2019-04-09 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
US10723707B2 (en) 2012-11-16 2020-07-28 Janssen Sciences Ireland Unlimited Company Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
US10259793B2 (en) 2013-02-21 2019-04-16 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
US10647684B2 (en) 2013-02-21 2020-05-12 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
US10829494B2 (en) 2013-03-29 2020-11-10 Janssen Sciences Ireland Unlimited Company Macrocyclic deaza-purinones for the treatment of viral infections
US11702426B2 (en) 2013-03-29 2023-07-18 Janssen Sciences Ireland Unlimited Company Macrocyclic deaza-purinones for the treatment of viral infections
US10266543B2 (en) 2013-03-29 2019-04-23 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
US10865193B2 (en) 2013-05-24 2020-12-15 Janssen Sciences Ireland Unlimited Company Pyridone derivatives for the treatment of viral infections and further diseases
US10377738B2 (en) 2013-05-24 2019-08-13 Janssen Sciences Ireland Unlimited Company Pyridone derivatives for the treatment of viral infections and further diseases
US9586958B2 (en) 2013-06-11 2017-03-07 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
US10385054B2 (en) 2013-06-27 2019-08-20 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US10781216B2 (en) 2013-06-27 2020-09-22 Janssen Sciences Ireland Unlimited Company Pyrrolo [3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US10822347B2 (en) 2013-07-30 2020-11-03 Janssen Sciences Ireland Unlimited Company Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
US10316043B2 (en) 2013-07-30 2019-06-11 Janssen Sciences Ireland Unlimited Company Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
WO2015165428A1 (fr) * 2014-04-30 2015-11-05 Masarykova Univerzita Furopyridines utilisées en tant qu'inhibiteurs de protéine kinases
US9902733B2 (en) 2014-04-30 2018-02-27 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
US11053256B2 (en) 2016-07-01 2021-07-06 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
US10968184B2 (en) 2016-09-29 2021-04-06 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
US11597704B2 (en) 2018-03-01 2023-03-07 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
US11858932B2 (en) 2020-08-12 2024-01-02 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Also Published As

Publication number Publication date
HRP970454B1 (en) 2002-10-31
SK23399A3 (en) 2000-08-14
CA2263566C (fr) 2003-09-09
AR015103A1 (es) 2001-04-18
NO313636B1 (no) 2002-11-04
ID18249A (id) 1998-03-19
ES2273369T3 (es) 2007-05-01
AP762A (en) 1999-09-13
HUP9903965A2 (hu) 2000-03-28
PL332040A1 (en) 1999-08-16
KR20000035934A (ko) 2000-06-26
GT199700095A (es) 1999-02-16
TNSN97145A1 (fr) 2005-03-15
JP2000502723A (ja) 2000-03-07
EA002769B1 (ru) 2002-08-29
DZ2300A1 (fr) 2002-12-25
BR9711970A (pt) 1999-08-24
CZ68199A3 (cs) 1999-11-17
DE69736711T2 (de) 2007-09-20
PE108898A1 (es) 1999-01-26
NO990927L (no) 1999-02-26
NZ333302A (en) 2000-08-25
ZA977687B (en) 1999-03-01
CA2263566A1 (fr) 1998-03-05
JP3621706B2 (ja) 2005-02-16
JP2005047930A (ja) 2005-02-24
AU3456197A (en) 1998-03-19
HRP970454A2 (en) 1998-08-31
EA199900165A1 (ru) 1999-08-26
AP9701077A0 (en) 1997-10-31
EP0923582A1 (fr) 1999-06-23
ATE340176T1 (de) 2006-10-15
TR199900389T2 (xx) 2000-06-21
IL127566A0 (en) 1999-10-28
NO990927D0 (no) 1999-02-26
AU735401B2 (en) 2001-07-05
IS4963A (is) 1999-01-29
OA10977A (en) 2001-11-02
TW575573B (en) 2004-02-11
HUP9903965A3 (en) 2002-02-28
BG103189A (en) 1999-09-30
MA26438A1 (fr) 2004-12-20
CO4600634A1 (es) 1998-05-08
CN1227554A (zh) 1999-09-01
PA8436201A1 (es) 1999-12-27
DE69736711D1 (de) 2006-11-02
EP0923582B1 (fr) 2006-09-20

Similar Documents

Publication Publication Date Title
EP0923582B1 (fr) Derives 6,5-hetero-bicycliques substitues
US6900217B2 (en) Substituted 6,5-hetero-bicyclic derivatives
CA2262692C (fr) Derives 6,6- ou 6,7-bicycliques contenant pyrido ou pyrimido substitues
AU726771B2 (en) Substituted 6,6-hetero-bicyclic derivatives
JP3457490B2 (ja) 置換されたヘテロ環誘導体
US20030114671A1 (en) Substituted6,6-hetero-bicyclicderivatives
US6992188B1 (en) Substituted heterocyclic derivatives
MXPA99002014A (en) Substituted 6,5-hetero-bicyclic derivatives
MXPA99001309A (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97197027.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 333302

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1199801051

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1997930697

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2263566

Country of ref document: CA

Ref document number: 2263566

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 23399

Country of ref document: SK

Ref document number: 1999/00389

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 199900165

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 1998 511429

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1999-681

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019997001674

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/002014

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1997930697

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-681

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 09242682

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1019997001674

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019997001674

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997930697

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1999-681

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1997930697

Country of ref document: EP